

Date: 07:03:2023

Urgent Field Safety Notice

Intersurgical Clear-Therm™ 3 HMEF with Luer Port and Retainable Cap

For Attention of*: All clinical staff, Managers and users of the above product

Contact details of local representative (name, e-mail, telephone, address etc.)*

Chris Randall
Wokingham Site Quality Manager
Intersurgical Ltd.
Crane House
Molly Millars Lane
Wokingham
Berkshire
RG41 2RZ

Email: priority@intersurgical.co.uk
Tel. No: 0118 9656 300
Fax: 0118 9656 356

Urgent Field Safety Notice (FSN)

Intersurgical Clear-Therm™ 3 HMEF with Luer Port and Retainable Cap

Risk addressed by FSN

1. Information on Affected Devices*	
1	1. Device Type(s)*
.	HMEF and combined Catheter mount derivatives
1	2. Commercial name(s)
.	Clear-Therm 3 HMEF with luer port and retainable cap Clear-Therm 3 HMEF with luer port, Superset™ catheter mount and elbow Clear-Therm 3 HMEF with luer port, Superset™ catheter mount, double swivel elbow
1	3. Unique Device Identifier(s) (UDI-DI)
.	N/A
1	4. Primary clinical purpose of device(s)*
.	To reduce risk of bacterial and viral contamination of patients, medical devices and equipment, whilst also reducing moisture and heat loss from the patient's respiratory gases within anaesthesia, critical and respiratory care breathing systems
1	5. Device Model/Catalogue/part number(s)*
.	Ref: 1541000 Ref; 1541974 Ref; 1541019
1	6. Software version
.	N/A
1	7. Affected serial or lot number range
.	Ref: 1541000 Lots: 1222605, 1230264 Ref; 1541974 Lots: 1222798, 1230062, 1230176, 1230235 Ref; 1541019 Lot: 1230061
1	8. Associated devices
.	N/A.

2. Reason for Field Safety Corrective Action (FSCA)*			
2	1. Description of the product problem*		
.	We have received reports of foam dust particles on the machine side housing of the HMEF and in the packaging, where it may come into contact with the patient side connection.		
2	2. Hazard giving rise to the FSCA*		
.	Whilst aesthetically undesirable the observed dust within the HMEF housing and packaging is unlikely to be released during use or compromise the patient's airway. However, there remains a possibility that it could come into contact with the patient.		
2	3. Probability of problem arising		
.	1:10,000 - 1:1,000		
2	4. Predicted risk to patient/users		
.	Moderate risk of harm and possible occurrence.		
2	5. Further information to help characterise the problem		
.	N/A		
2	6. Background on Issue		
.	Intersurgical has received reports, where unacceptable amounts of dust particles from the foam HME element have been found in the machine side housing or in the packaging of the products. In all reports it has been visually obvious and noticed either whilst still in the pack, or during pre-use checks. This issue has been due to a process non-conformity during the manufacture of the HME material.		
2	7. Other information relevant to FSCA		
.	The manufacturing process for the HME material has been investigated and resolved.		
3. Type of Action to mitigate the risk*			
3.	1. Action To Be Taken by the User* <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <input checked="" type="checkbox"/> Identify Device <input checked="" type="checkbox"/> Quarantine Device <input checked="" type="checkbox"/> Return Device <input checked="" type="checkbox"/> Destroy Device </div> <div style="margin-top: 10px;"> <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Follow patient management recommendations <input type="checkbox"/> Take note of amendment/reinforcement of Instructions For Use (IFU) <input type="checkbox"/> Other <input type="checkbox"/> None </div> <p style="margin-top: 20px;">Identify and immediately quarantine all affected codes and lot numbers listed above and do not use these devices. Please complete the Reply Form to confirm the products have been disposed of locally or to arrange collection of the devices and a credit. If you have no affected devices in stock, please confirm this using the Reply Form. Return the completed Reply Form to priority@intersurgical.co.uk.</p> <p>Please continue to report to Intersurgical any adverse events involving this product.</p>		
3.	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">2. By when should the action be completed?</td> <td>Immediately on receipt of this FSN and ongoing until no affected stock listed in this FSN is remaining.</td> </tr> </table>	2. By when should the action be completed?	Immediately on receipt of this FSN and ongoing until no affected stock listed in this FSN is remaining.
2. By when should the action be completed?	Immediately on receipt of this FSN and ongoing until no affected stock listed in this FSN is remaining.		

3.	3. Particular considerations for: Is follow-up of patients or review of patients' previous results recommended? Not applicable.	
3.	4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes
3.	5. Action Being Taken by the Manufacturer <div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> Product Removal <input type="checkbox"/> Software upgrade <input type="checkbox"/> Other </div> <div> <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> IFU or labelling change <input type="checkbox"/> None </div> </div>	
3	6. By when should the action be completed?	One month of receipt of the FSN
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet? No	

4. General Information*		
4.	1. FSN Type*	New - Recall
4.	2. For updated FSN, reference number and date of previous FSN	N/A
4.	3. For Updated FSN, key new information as follows: N/A	
4.	4. Further advice or information already expected in follow-up FSN? *	No
4	5. If follow-up FSN expected, what is the further advice expected to relate to: N/A	
4	6. Anticipated timescale for follow-up FSN	N/A
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)	
	a. Company Name	Intersurgical Ltd.
	b. Address	Crane House, Molly Millars Lane, Wokingham, Berkshire, RG41 2RZ
	c. Website address	https://www.intersurgical.com/
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *	
4.	9. List of attachments/appendices:	Customer Reply Form

4.	10. Name/Signature	Ivan Seniut Group Quality and Regulatory Affairs Director Duly authorised for and on behalf of Intersurgical Ltd 
----	--------------------	--

Transmission of this Field Safety Notice	
	<p>This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)</p> <p>Please transfer this notice to other organisations on which this action has an impact. (As appropriate)</p> <p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback..*</p>

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.